Olerile Livesey D
The School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820914308. doi: 10.1177/1533033820914308.
Of colloidal systems, ceteris paribus, nanostructured lipid carriers are second to none in offering a single-unit platform for multifunctional benefits. Quantum dots are known to possess unique properties that make them ideal for imaging purpose and that they may be used for cancer detection. For several decades, paclitaxel has been the most effective drug against a wide range of solid tumours. Theragnostic nanomedicine provides a platform to monitor, evaluate, and individualize treatment in real time. Evaluation of cancer treatment outcome at an early stage therapy is key to increase survival prospects of a patient. Previously, a novel co-loaded nanostructured lipid carriers' theragnostic system for parenteral administration was developed. The aim of this study was to further investigate the co-loaded nanostructured lipid carriers in order to provide interpretation necessary for preclinical elucidation of the formulation, in part. The co-loaded nanostructured lipid carriers were prepared by oil/water emulsification-solvent evaporation technique. In this study, stability and co-loaded nanostructured lipid carriers' internalization by MCF 7 and HepG2 cells were investigated. The co-loaded nanostructured lipid carriers was stable at 4°C for 1 month. The formulation was successfully internalized by MCF-7 and HepG2 cells. Nevertheless, the co-loaded nanostructured lipid carrier was more apt for MCF-7 cells. This finding affirms the formulation to be the most appropriate for breast cancer treatment. In addition, if taken correctly by a patient for a month, the formulation would give true reflection of the contents' amounts, the factor paramount to appropriate changes in treatment protocol. It can therefore safely be concluded that the co-loaded nanostructured lipid carrier formulation may be potentially an effective theragnostic translational system.
在胶体系统中，在其他条件相同的情况下，纳米结构脂质载体在提供多功能益处的单一单元平台方面首屈一指。量子点具有独特的性质，使其非常适合用于成像目的，并且可用于癌症检测。几十年来，紫杉醇一直是对抗多种实体瘤最有效的药物。治疗诊断纳米医学提供了一个实时监测、评估和个性化治疗的平台。在早期治疗阶段评估癌症治疗结果是提高患者生存前景的关键。此前，已经开发出一种用于肠胃外给药的新型共载纳米结构脂质载体治疗诊断系统。本研究的目的是进一步研究共载纳米结构脂质载体，以便部分地为该制剂的临床前阐释提供必要的解释。共载纳米结构脂质载体通过油/水乳化-溶剂蒸发技术制备。在本研究中，研究了共载纳米结构脂质载体在4℃下1个月的稳定性以及其被MCF 7和HepG2细胞内化的情况。共载纳米结构脂质载体在4℃下1个月内稳定。该制剂成功被MCF-7和HepG2细胞内化。然而，共载纳米结构脂质载体更易于被MCF-7细胞摄取。这一发现证实该制剂最适合用于乳腺癌治疗。此外，如果患者正确服用该制剂一个月，它将真实反映其中成分的含量，这是治疗方案适当调整的至关重要因素。因此，可以有把握地得出结论，共载纳米结构脂质载体制剂可能是一种有效的治疗诊断转化系统。
